EICHORCondition: Atopic Dermatitis · Sponsor: Charite University, Berlin, Germany
Interested? Contact the study team ↓
Sponsor, CRO or site team? See where this study is running → — listed sites, countries and recruiting context. Everything below is written for patients and caregivers.
Currently, patients with moderate to severe atopic dermatitis are treated with dupilumab if unresponsive to topical treatment. However, not all patients who suffer from atopic dermatitis respond similarly to this treatment. Pattern recognition of immune cells (PRI) is an efficient method to screen patients to allow a more personalized therapy. The main aim of this scientific explorative study is to unravel the changes in peripheral blood immune cell compositions in patients with atopic eczema undergoing dupilumab treatment. This allows the identification of phenotypes of treatment responders and non-responders and possible approaches of treatment modifications for non-responders.
This description comes directly from the study's public registry record.
Contact details are listed per location below or on the registry record.
There is no obligation to join — the study team can answer your questions about taking part.
Always discuss trial participation with your own doctor first.
Inclusion Criteria: * Age 18 and above * Diagnosis of atopic dermatitis for ≥1 year * Inadequate response to treatment with topical medications * Confirmed dupilumab treatment Exclusion Criteria: * Age below 18 * Known or suspected allergy or reaction to any component of the dupilumab formulation * Known active allergic or irritant contact dermatitis that is likely to interfere with the assessment of the severity of AD * Severe conjunctivitis or blepharitis
Reproduced word-for-word from the public registry record — the study team can answer questions about it.
| Dpt of Dermatology and Allergology, Charité - Universitätsmedizin Berlin | Berlin, Germany | Recruiting |
This study lists sites in the areas below. Each link shows other recruiting studies near that city, from the public registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05098821